

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Celltrion, Inc.
Petitioner,
v.

Genentech, Inc.
Patent Owner

Patent No. 6,407,213

Inter Partes Review No. IPR2017-01374

PETITIONER'S THIRD UPDATED MANDATORY NOTICES

Celltrion, Inc. hereby updates its Mandatory Notices pursuant to 37 C.F.R. § 42.8(a)(3) to add related matters.

A. REAL PARTIES-IN-INTEREST (37 C.F.R. § 42.8(b)(1)) (No Change)

The real parties-in-interest are Celltrion, Inc. (“Petitioner”), Celltrion Healthcare Co. Ltd. (“CTHC”), and Teva Pharmaceuticals International GmbH (“Teva”).

B. RELATED MATTERS (37 C.F.R. § 42.8(b)(2)) (Updated)

Patent No. 6,407,213 (“the ’213 patent”) is related to the following patents: U.S. Pat. Nos. 6,639,055, 6,800,738, and 6,719,971 (all expired for maintenance fee non-payment), and U.S. Pat. No. 8,075,890.

Petitioner additionally challenged claims of the ’213 patent in IPR2017-01373, which was instituted. Pfizer Inc. challenged the ’213 patent in IPR2017-01488 and IPR2017-01489, which were both instituted. Boehringer Ingelheim Pharmaceuticals, Inc. challenged the ’213 patent in IPR2017-02031 and IPR2017-02032. Samsung Bioepis Co., Ltd. challenged the ’213 patent in IPR2017-02139 and IPR2017-02140, and has moved to join these proceedings with IPR2017-01488 and IPR2017-01489, respectively.

The ’213 patent is at issue in the following litigations: *Amgen Inc v. Genentech, Inc. et al*, No. 2-17-cv-07349 (C.D. Cal.); *Genentech, Inc. et al v.*

Amgen Inc., No. 1-17-cv-01407 (D. Del.); *Genentech, Inc. et al v. Amgen Inc.*, No. 1-17-cv-01471 (D. Del.); *Genentech, Inc. v. Pfizer, Inc.*, No. 1-17-cv-01672 (D. Del.); *Celltrion, Inc. v. Genentech, Inc.*, No. 3-18-cv-274 (N.D. Cal); and *Genentech, Inc. v. Celltrion, Inc.*, No. 1-18-cv-095 (D. Del.).

C. IDENTIFICATION OF COUNSEL AND SERVICE INFORMATION (37 C.F.R. § 42.8(b)(3) & (4)) (No Change)

Lead counsel is Cynthia Lambert Hardman, Reg. No. 53,179 (chardman@goodwinlaw.com), and backup counsel is Robert V. Cerwinski (motion for seek *pro hac vice* admission submitted) (rcerwinski@goodwinlaw.com). Counsel are with Goodwin Procter LLP, 620 Eighth Avenue, New York, NY, 10018, Tel. (212) 813- 8800, Fax (212) 355-3333. Please direct all correspondence counsel using this contact information. Petitioner consents to electronic mail service: chardman@goodwinlaw.com and rcerwinski@goodwinlaw.com.

Dated: January 26, 2018

By: /Cynthia Lambert Hardman/
Cynthia Lambert Hardman (Reg. No. 53,179)
Robert V. Cerwinski (motion for seek *pro hac vice* admission submitted)
GOODWIN PROCTER LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018
(212) 813-8800 (telephone)
(212) 355-3333 (facsimile)

Counsel for Petitioner

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 26 day of January, 2018, I caused a copy of this PETITIONER'S THIRD UPDATED MANDATORY NOTICES to be served by email on the lead and back up counsel for Patent Owners at:

David Cavanaugh (David.Cavanaugh@wilmerhale.com)

Rebecca Whitfield (Rebecca.Whitfield@wilmerhale.com)

Robert Gunther (Robert.Gunther@wilmerhale.com)

Adam Brausa (abrausa@durietangri.com)

Daralyn Durie (ddurie@durietangri.com)

Andrew Danford (Andrew.Danford@wilmerhale.com)

Lisa Pirozzolo (Lisa.Pirozzolo@wilmerhale.com)

Kevin Prussia (Kevin.Prussia@wilmerhale.com)

/Cynthia Lambert Hardman/

Cynthia Lambert Hardman (Reg. No. 53,179)

GOODWIN PROCTER LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018
(212) 813-8800 (telephone)
(212) 355-3333 (facsimile)